OneSource Specialty Pharma Limited reported robust Q1 financial performance with 12% revenue growth to INR 3,273 million and 37% EBITDA growth to INR 885 million. The company is accelerating capacity expansion for drug-device combinations and exploring potential acquisitions in Poland and India. These acquisitions could add $100 million in revenue potential by FY27. OneSource also announced a strategic partnership with Xbrane Biopharma to strengthen its drug substance business.
OneSource Specialty Pharma Explores Acquisition of Sterile Injectable Businesses, Reports Q1 Results Aug 04, 2025
ONESOURCE Specialty Pharma Secures VAI Classification from USFDA for Bangalore Facility Jun 10, 2025
OneSource Specialty Pharma's Unit 2 Secures ANVISA GMP Certification, Expanding Market Reach to Brazil Apr 10, 2025
More news about Onesource Specialty Pharma
07Mar 25
SEBI Guidance Halts OneSource Specialty Pharma's QIP Plans Post-Listing
OneSource Specialty Pharma, a newly listed pharmaceutical company, faces a setback in its capital raising plans due to SEBI guidance. The company is prohibited from conducting a Qualified Institutional Placement (QIP) immediately after listing, owing to its involvement in a merger with an unlisted entity prior to going public. SEBI mandates a one-year waiting period post-listing before OneSource can initiate a QIP. This delay may impact the company's short-term growth strategies and force it to seek alternative funding sources.